Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of imalumab (BAX69) plus 5-FU/leucovorin or panitumumab vs standard of care in metastatic colorectal cancer
2015-000896-28Phase 2Terminated
- Sponsor
- Baxalta
- Start
- Aug 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of imalumab in metastatic colorectal adenocarcinoma (mCRC) (3 arms), sponsored by Baxalta. Primary endpoints: Recommended Phase 2 dose (RP2D) of imalumab in combination with 5-FU/leucovorin or panitumumab (Part 1) and Safety and tolerability of imalumab combinations. Started Aug 2015; status: terminated.
02
Drugs
imalumab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2015-000896-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000896-28.